Sawai Group Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Sawai Group Holdings şirketinin toplam hissedar öz sermayesi ¥201.2B ve toplam borcu ¥93.4B olup, bu da borç-öz sermaye oranını 46.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥363.7B ve ¥162.5B dir. Sawai Group Holdings 'in FAVÖK'ü ¥19.5B faiz karşılama oranı 43.5 dur. Şirketin ¥49.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

46.4%

Borç/özkaynak oranı

JP¥93.36b

Borç

Faiz karşılama oranı	43.5x
Nakit	JP¥49.66b
Eşitlik	JP¥201.21b
Toplam yükümlülükler	JP¥162.54b
Toplam varlıklar	JP¥363.75b

Son finansal sağlık güncellemeleri

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Jul 27

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Mar 06

Recent updates

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sep 04

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 12

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Jul 27

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

May 28

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Apr 22

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4887 'nin kısa vadeli varlıkları ( ¥214.9B ) kısa vadeli yükümlülüklerini ( ¥74.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4887 şirketinin kısa vadeli varlıkları ( ¥214.9B ) uzun vadeli yükümlülüklerini ( ¥88.1B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4887 'nin net borç/öz sermaye oranı ( 21.7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 4887 şirketinin borç/öz sermaye oranı son 5 yılda 34.7% seviyesinden 46.4% seviyesine yükseldi.

Borç Kapsamı: 4887 'nin borcu işletme nakit akışı ( 21.4% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 4887 'in borcuna ilişkin faiz ödemeleri EBIT ( 43.5 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Sawai Group Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Recent updates

Upcoming dividend of JP¥78.00 per share

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Final dividend of JP¥78.00 announced

Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.

Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Consensus EPS estimates increase by 24%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Now 21% undervalued

Upcoming dividend of JP¥65.00 per share

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Consensus EPS estimates increase by 11%, revenue downgraded

Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024

Consensus EPS estimates increase by 40%, revenue downgraded

Now 21% undervalued

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to JP¥5,863

Price target increased by 7.3% to JP¥5,586

Consensus EPS estimates fall by 12%

Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Upcoming dividend of JP¥65.00 per share at 2.8% yield

Price target increased by 9.9% to JP¥4,734

Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Price target increased by 7.5% to JP¥4,308

First quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 14%

Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023

Price target decreased by 9.2% to JP¥4,169

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Announces Dividend for the Second Quarter Ending September 30, 2022, Payable on December 2, 2022; Provides Dividend Guidance for the Year Ending March 31, 2023

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Price target increased to JP¥4,630

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2023

Price target decreased to JP¥4,561

Sawai Group Holdings Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. Announce Notice of Filing an Appeal in Patent Infringement Lawsuit Concerning Edirol Capsule

Sawai Group Holdings Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Sawai Group Holdings Co., Ltd. Provides Earnings Guidance for Period Ending September 2022 and Year Ending March 2023

Consensus EPS estimates fall by 83%

Less than half of directors are independent

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Sawai Pharmaceutical Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥71.13 (vs JP¥122 in 2Q 2021)

Upcoming dividend of JP¥65.00 per share

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin